Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DON in Pediatric Cerebral Malaria
NCT05478720Phase 2Recruiting
- Start
- Aug 2022
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 6-Diazo-5-oxo-L-norleucine in cerebral malaria (CM), malaria. Started Aug 2022; status: recruiting.
02
Drugs
6-Diazo-5-oxo-L-norleucine
03
Conditions
cerebral malaria (CM)malaria
Beyond the preview
Go deeper on NCT05478720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478720.